TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00619983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: Group 1: Will receive donepezil 5mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: Group 2: Will receive duloxetine 30 mg twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil 2.5 mg and duloxetine 30mg
Description: Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Group 4: Will receive placebo pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: Week 8: all subjects will have open label gabapentin added to their randomized study medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: Week 8: all subjects will have open label gabapentin added to their randomized study medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: Week 8: all subjects will have open label gabapentin added to their randomized study medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gabapentin
Description: Week 8: all subjects will have open label gabapentin added to their randomized study medication
Study: NCT04546659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retrowalking
Description: Treatment of retro-walking including supervised 10 min retro-walking training with 5 min of warm-up and cool down on a flat surface at their comfortable speed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Therapy
Description: Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Treatment of conventional therapy involve Isometric Quadriceps exercise, SLR, Isometric hip adduction exercises, Terminal knee extension exercise 1 set of 10 Reps twice a day.
Study: NCT01984671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Pain Coping Skills Training
Study: NCT00809341

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m\^2 on Day 1 of each cycle as part of R-CHOP or R-ICE. Also given 375 mg/m\^2 on Days 1, 30, and 37 as part of HiCy.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m\^2 on Day 1 of each cycle as part of R-CHOP or R-ICE. Also given 375 mg/m\^2 on Days 1, 30, and 37 as part of HiCy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 750 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
Study: NCT00630591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner-Assisted Tailored Intervention
Description: Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
Study: NCT03362801

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: sarcopenia and mobility measurement
Description: walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: sarcopenia and mobility measurement
Description: walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment
Study: NCT02694458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early vancomycin monitoring and bayesian dosage adjustment
Description: Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach. Then measure of vancomycin serum concentration at the 24th hour of treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: usual vancomycin dose and monitoring strategy
Description: Vancomycin serum concentration will be measured at the 24th hour of treatment.
Study: NCT01678703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laminaria, MedGyn Products, Inc. USA.
Description: Insertion of Hygroscopic laminarias into the cervical canal for preparation prior to late surgical abortion. The number of laminarias is according to the cervical compliance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
Study: NCT03822494

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife SBRT
Description: Radiation Therapy
Study: NCT01715519

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment (Viibryd)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment (Viibryd)
Study: NCT03745105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Description: prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piroxicam Injectable Solution
Description: prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine HCL
Description: prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml
Study: NCT01935713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex
Description: Participants were given the choice of 2mg or 4mg lozenges depending on how many cigarettes per day they reported to smoke.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette
Description: Participants were given an e-cigarette starter kit, charging case, and cartridges in either 12mg or 16 mg nicotine, depending on their current amount of cigarettes smoked per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dissolvable Tobacco Lozenge
Description: Participants were given Ariva (light to moderate smokers) or Stonewall (heavier smokers, \>2 packs per day).
Study: NCT02103257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequential Icotinib Plus Chemotherapy
Description: Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icotinib
Description: Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
Study: NCT05528484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERAS nursing
Description: Patients were given education before surgery, fluid and anesthetic drug management during surgery, early ambulation, fluid management and early feeding after surgery, etc

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non eras nursing
Description: Patients were under the routine management without eras protocol
Study: NCT01448863

Intervention type: OTHER
Intervention: Culture medium metabolomic analysis
Description: During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile.

Intervention type: OTHER
Intervention: Culture medium metabolomic analysis
Description: During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile.

Intervention type: OTHER
Intervention: Culture medium metabolomic analysis
Description: During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile.
Study: NCT00819572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLX105, a single-chain (scFv) antibody fragment against TNF-alpha
Description: Comparison of two different doses of intra-articular DLX105

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DLX105, a single-chain (scFv) antibody fragment against TNF-alpha
Description: Comparison of two different doses of intra-articular DLX105

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04667533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desidustat
Description: A total of 24 participants will be enrolled.~The study is divided into three cohorts as given below:~1. Cohort I: Single-dose 100 mg~2. Cohort II: Single-dose 150 mg~3. Cohort III: Single-dose 200 mg
Study: NCT01530724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-loss diet strategy (+) exercise (PA)
Description: Weight-loss diet strategy with a free gym membership; monthly 60-minute educational workshops; 3 sessions of workout per week of mostly aerobic training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-loss diet strategy (+) exercise (PA)
Description: Weight-loss diet strategy with a free gym membership; monthly 60-minute educational workshops; 3 sessions of workout per week of mostly aerobic training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight loss (-) exercise (PA)
Description: Weight-loss diet strategy without exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight loss (-) exercise (PA)
Description: Weight-loss diet strategy without exercise
Study: NCT01375634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg intravenous over 2 minutes For patients \>60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: 2 mg intravenous over 2 minutes For patients \>60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
Study: NCT00763516

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiation and chemotherapy
Description: Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only~Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks~Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation~Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses
Study: NCT00928655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetazolamide
Description: acetazolamide 250mg 1/0/2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nocturnal continuous positive airway pressure
Description: continuous positive airway pressure

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nocturnal continuous positive airway pressure
Description: continuous positive airway pressure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study: NCT00382109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study: NCT00809341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 50 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 1.4 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
Study: NCT00382109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV or orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given orally

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: total body irradiation
Description: Part of the transplant preparatory regimen

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: Part of the transplant preparatory regimen
Study: NCT01159639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
Study: NCT03655873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC30654AcOH capsule
Description: single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg HEC30654AcOH capsule in day1.~Multiple ascending-dose study:~15-、30-、60mgHEC30654AcOH capsule in day1-day7，2 times everyday.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg placebo capsule in day1.~Multiple ascending-dose study:~15-、30-、60mg placebo capsule in day1-day7，2 times everyday.
Study: NCT02668237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OptiPAC
Description: Molecular and urinary tests.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Antibiotics for prevention.
Study: NCT01941004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod
Description: Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (6mos) + open label fingolimod (6 mos)
Description: Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
Study: NCT02415998

Intervention type: PROCEDURE
Intervention: TEE
Description: Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
Study: NCT02773264

Intervention type: DEVICE
Intervention: Ultrasound
Description: Ultrasound Elastography of soft tissue and organ lesions
Study: NCT01736358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketoralac
Description: 15.75 mg of Sprix in each nostril 20 minutes before end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
Study: NCT01695122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Study: NCT01132196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium DR Tablets 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium DR Tablets 500 mg
Study: NCT01097460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MM-111 + Herceptin
Description: For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
Study: NCT04039503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC as add-on to the pre-trial background medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC as add-on to the pre-trial background medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC as add-on to the pre-trial background medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC as add-on to the pre-trial background medication.
Study: NCT02413684

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient engagement toolkit
Description: Pack Health LLC and Duke will develop a patient engagement toolkit known as Packs to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care
Study: NCT04436796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: interoperable Artificial Pancreas System (iAPS)
Description: Use of the iAPS at home for 13 weeks, with weekly adaptation of insulin delivery settings occurring automatically in the iAPS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS)
Description: Use of personal pump with study CGM \& glucometer at home for 13 weeks.
Study: NCT04005729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cangrelor 50 MG
Description: 30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
Study: NCT02427555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Barley kernel bread
Description: 3 days intervention with barley kernel bread

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: white wheat bread
Description: 3 days intervention with white wheat bread
Study: NCT00245011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Ifosfamide administered IV.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sm-EDTMP (low dose)
Description: Sm-EDTMP (low dose) administered after autologous stem cell collection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: sm-EDTMP (higher dose)
Description: Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
Study: NCT02708602

Intervention type: GENETIC
Intervention: β2AR polymorphism

Intervention type: GENETIC
Intervention: β2AR polymorphism

Intervention type: GENETIC
Intervention: β2AR polymorphism

Intervention type: GENETIC
Intervention: β2AR polymorphism

Intervention type: GENETIC
Intervention: β2AR polymorphism

Intervention type: GENETIC
Intervention: β2AR polymorphism
Study: NCT02429921

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high-selenium lentils
Description: lentils grown on naturally selenium-rich soils in the Canadian Prairies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-Se lentils
Description: lentils grown on selenium-deficient soils in Idaho, USA.
Study: NCT02101099

Intervention type: DEVICE
Intervention: Colonoscopy Force Monitor
Description: Use of Colonoscopy Force Monitoring device (CFM) to measure forces applied to the colonoscope during the procedure.
Study: NCT06336499

Intervention type: OTHER
Intervention: Multi-parametric MRI and image analysis by deep learning or machine learning algorithms
Description: Diagnosis models are established using quantitative features extracted from the multi-parametric MRI images and further processed by appropriate deep learning or machine learning algorithms.

Intervention type: OTHER
Intervention: Multi-parametric MRI and image analysis by deep learning or machine learning algorithms
Description: Diagnosis models are established using quantitative features extracted from the multi-parametric MRI images and further processed by appropriate deep learning or machine learning algorithms.
Study: NCT03040687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti CS6 BSIgG product (Lot PD1601105CS)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti B7A BSIgG product (Lot PD1601132ET)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bovine Immunoglobin Negative Control (Lot PD161071NC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B7A- CS6-expressing ETEC challenge strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B7A- CS6-expressing ETEC challenge strain

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B7A- CS6-expressing ETEC challenge strain
Study: NCT04157686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 1
Description: MT10109L Dose 1 will be injected into the GL area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 1
Description: MT10109L Dose 1 will be injected into the GL area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 2
Description: MT10109L Dose 2 will be injected into the LCL area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 2
Description: MT10109L Dose 2 will be injected into the LCL area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 1 + Dose 2
Description: MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 1 + Dose 2
Description: MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 1 + Dose 2
Description: MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L Dose 1 + Dose 2
Description: MT10109L Dose 1 will be injected into the GL area plus MT10109L Dose 2 will be injected into the LCL area